Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:ACOG)

8.160 UNCHANGED
Last Price Updated: 3:55 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACOG

News headline image
Alpha Cognition Announces Partial Exercise of Over-allotment Option
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Voluntary Delisting from CSE
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq Uplisting
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Appointment of VP Finance and Accounting
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Change of Officer
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
From Alpha Cognition Inc.
Via Business Wire
News headline image
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Alpha Cognition to Present at the Life Science Investor Forum March 7th
Company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Provides Business Update
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
News headline image
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Investor Forum Agenda Announced for June 22nd
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Alpha Cognition Launches $6.5 Million Private Placement
From Alpha Cognition Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.